Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages - PubMed (original) (raw)
Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages
S Hortelano et al. J Immunol. 2000.
Abstract
Activation of the macrophage cell line RAW 264.7 with LPS and IFN-gamma induces apoptosis through the synthesis of high concentrations of NO due to the expression of NO synthase-2. In addition to NO, activated macrophages release other molecules involved in the inflammatory response, such as reactive oxygen intermediates and PGs. Treatment of macrophages with cyclopentenone PGs, which are synthesized late in the inflammatory onset, exerted a negative regulation on cell activation by impairing the expression of genes involved in host defense, among them NO synthase-2. However, despite the attenuation of NO synthesis, the percentage of apoptotic cells increased with respect to activated cells in the absence of cyclopentenone PGs. Analysis of the mechanisms by which these PGs enhanced apoptosis suggested a potentiation of superoxide anion synthesis that reacted with NO, leading to the formation of higher concentrations of peroxynitrite, a more reactive and proapoptotic molecule than the precursors. The effect of the cyclopentenone 15-deoxy-Delta(12,14)-PGJ(2) on superoxide synthesis was dependent on p38 mitogen-activated protein kinase activity, but was independent of the interaction with peroxisomal proliferator-activated receptor gamma. The potentiation of apoptosis induced by cyclopentenone PGs involved an increase in the release of cytochrome c from the mitochondria to the cytosol and in the nitration of this protein. These results suggest a role for cyclopentenone PGs in the resolution of inflammation by inducing apoptosis of activated cells.
Similar articles
- Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling.
Nencioni A, Lauber K, Grünebach F, Van Parijs L, Denzlinger C, Wesselborg S, Brossart P. Nencioni A, et al. J Immunol. 2003 Nov 15;171(10):5148-56. doi: 10.4049/jimmunol.171.10.5148. J Immunol. 2003. PMID: 14607914 - Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages.
Castrillo A, Través PG, Martín-Sanz P, Parkinson S, Parker PJ, Boscá L. Castrillo A, et al. Mol Cell Biol. 2003 Feb;23(4):1196-208. doi: 10.1128/MCB.23.4.1196-1208.2003. Mol Cell Biol. 2003. PMID: 12556480 Free PMC article. - A proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: oxidative stress-induced extracellular signal-regulated kinase activation without NF-kappa B inhibition.
Bureau F, Desmet C, Mélotte D, Jaspar F, Volanti C, Vanderplasschen A, Pastoret PP, Piette J, Lekeux P. Bureau F, et al. J Immunol. 2002 May 15;168(10):5318-25. doi: 10.4049/jimmunol.168.10.5318. J Immunol. 2002. PMID: 11994490 - Cyclopentenone prostaglandin receptors.
Negishi M, Katoh H. Negishi M, et al. Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:611-7. doi: 10.1016/s0090-6980(02)00059-x. Prostaglandins Other Lipid Mediat. 2002. PMID: 12432947 Review. - Effect of prostaglandins on the regulation of tumor growth.
Ishihara S, Rumi MA, Okuyama T, Kinoshita Y. Ishihara S, et al. Curr Med Chem Anticancer Agents. 2004 Jul;4(4):379-87. doi: 10.2174/1568011043352902. Curr Med Chem Anticancer Agents. 2004. PMID: 15281909 Review.
Cited by
- Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity.
Musiek ES, Milne GL, McLaughlin B, Morrow JD. Musiek ES, et al. Brain Pathol. 2005 Apr;15(2):149-58. doi: 10.1111/j.1750-3639.2005.tb00512.x. Brain Pathol. 2005. PMID: 15912888 Free PMC article. Review. - PPAR and immune system--what do we know?
Zhang X, Young HA. Zhang X, et al. Int Immunopharmacol. 2002 Jul;2(8):1029-44. doi: 10.1016/s1567-5769(02)00057-7. Int Immunopharmacol. 2002. PMID: 12349941 Free PMC article. Review. - Tripterine prevents endothelial barrier dysfunction by inhibiting endogenous peroxynitrite formation.
Wu F, Han M, Wilson JX. Wu F, et al. Br J Pharmacol. 2009 Jul;157(6):1014-23. doi: 10.1111/j.1476-5381.2009.00292.x. Epub 2009 Jun 5. Br J Pharmacol. 2009. PMID: 19508391 Free PMC article. - TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection.
Zganiacz A, Santosuosso M, Wang J, Yang T, Chen L, Anzulovic M, Alexander S, Gicquel B, Wan Y, Bramson J, Inman M, Xing Z. Zganiacz A, et al. J Clin Invest. 2004 Feb;113(3):401-13. doi: 10.1172/JCI18991. J Clin Invest. 2004. PMID: 14755337 Free PMC article. - Immunomodulatory effects of Hedysarum polybotrys extract in mice macrophages, splenocytes and leucopenia.
Huang GC, Lee CJ, Wang KT, Weng BC, Chien TY, Tseng SH, Wang CC. Huang GC, et al. Molecules. 2013 Dec 3;18(12):14862-75. doi: 10.3390/molecules181214862. Molecules. 2013. PMID: 24300120 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources